{"id":2209,"date":"2021-11-23T08:21:09","date_gmt":"2021-11-23T08:21:09","guid":{"rendered":"https:\/\/deon.qodeinteractive.com\/?page_id=2209"},"modified":"2022-11-10T21:11:10","modified_gmt":"2022-11-10T21:11:10","slug":"news","status":"publish","type":"page","link":"https:\/\/odwstage.com\/dev.pictor.dx\/news\/","title":{"rendered":"News"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t

\n\t\t\t\t\tLatest News\t\t\t<\/h1>\n\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t
\n\t\t
\n\t
\n\t\t
\n\t<\/div>\n\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\n\t\t\t\t7 February 2024\t<\/a>\n<\/div>\n
\n\t\tAnimal Health<\/a><\/span>Human Health<\/a><\/span>PRESS RELEASE<\/a><\/span>Technology<\/a><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t
\n\t\t\t\t

\n\t\n\t\tDisrupting a market, not creating one\t<\/a>\n<\/h4>\n\t\t

\n\t\t\tArticle from the “CAFFEINE” – The daily for New Zealand’s Startups What kiwi founders could learn from the turnaround at Auckland biotech company Pictor under new CEO Jamie Platt. Click here for the full article\t\t<\/p>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/article>\n

\n\t
\n\t\t
\n\t<\/div>\n\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\n\t\t\t\t17 December 2023\t<\/a>\n<\/div>\n
\n\t\tAnimal Health<\/a><\/span>PRESS RELEASE<\/a><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t
\n\t\t\t\t

\n\t\n\t\tPICTOR LAUNCHES NOVEL BEST-IN-CLASS M. bovis TEST AS NEW OUTBREAK HITS NZ\t<\/a>\n<\/h4>\n\t\t

\n\t\t\tPictor Limited, a New Zealand based biotechnology company, has launched a ground-breaking M. bovis test for global markets. Launch of the Pictor PictVet\u2122 Mycoplasma bovis Multiplex ELISA Kit comes at a time when new cases of M. bovis have been found in Canterbury. Pictor Managing Director, Dr. Jamie Platt says: \u201cAfter several years in development […]\t\t<\/p>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/article>\n

\n\t
\n\t\t
\n\t<\/div>\n\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\n\t\t\t\t6 December 2022\t<\/a>\n<\/div>\n
\n\t\tAnimal Health<\/a><\/span>Human Health<\/a><\/span>PRESS RELEASE<\/a><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t
\n\t\t\t\t

\n\t\n\t\tPictor announces funding round after successful launch in New Zealand and USA of SARS-CoV-2 Antibody Test\t<\/a>\n<\/h4>\n\t\t

\n\t\t\t$5 million raise to accelerate global market development and product development AUCKLAND, New Zealand, December 05, 2022— Pictor, a global leader in immunodiagnostics, today announced a funding round to help accelerate pipeline product development projects along with market development activities within Australia\/New Zealand, the US and Europe for its Human Health and Animal Health portfolios. This […]\t\t<\/p>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/article>\n

\n\t
\n\t\t
\n\t<\/div>\n\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\n\t\t\t\t16 November 2022\t<\/a>\n<\/div>\n
\n\t\tHuman Health<\/a><\/span>PRESS RELEASE<\/a><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t
\n\t\t\t\t

\n\t\n\t\tPictor and Rako Science bring improved access to COVID-19 antibody testing for New Zealand with technology from Tasso\t<\/a>\n<\/h4>\n\t\t

\n\t\t\tNovember 16, 2022 12pm NZDT AUCKLAND, New Zealand — Pictor, a global leader in immunodiagnostics, today announced that its PictArray\u2122 SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test will soon be available in New Zealand. Rako Science will utilize its national network by collecting blood samples with a device from Tasso, Inc., and undertake testing […]\t\t<\/p>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/article>\n

\n\t
\n\t\t
\n\t\t
\n\t\t\n\t\t\t\"\"\t\t<\/a>\n\t\t\t<\/div>\n<\/div>\n\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\n\t\t\t\t13 April 2022\t<\/a>\n<\/div>\n
\n\t\tHuman Health<\/a><\/span>PRESS RELEASE<\/a><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t
\n\t\t\t\t

\n\t\n\t\tBolstered By Investment, Pictor Partners with Mobility Health to Offer PictArray\u2122 SARS-CoV-2 Antibody Test, Indicating Whether Patients Require COVID-19 Booster\t<\/a>\n<\/h4>\n\t\t

\n\t\t\tFollowing a new investment of $6.1 million (NZD $8.8 million), biotech company Pictor today announced a partnership with U.S. laboratory service provider Mobility Health, launching a new antibody test as an important advance in COVID-19 monitoring and treatment. The investment, led by former Morrison & Co CEO Marko Bogoievski, and specialist growth investor K One W One Ltd. (K1W1), will support market and product development of the new antibody test and other Pictor in vitro diagnostics.\t\t<\/p>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/article>\n

\n\t
\n\t\t
\n\t\t
\n\t\t\n\t\t\t\"\"\t\t<\/a>\n\t\t\t<\/div>\n<\/div>\n\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\n\t\t\t\t20 January 2022\t<\/a>\n<\/div>\n
\n\t\tHuman Health<\/a><\/span>PRESS RELEASE<\/a><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t
\n\t\t\t\t

\n\t\n\t\tPictor Successfully Completes Validation Trial in U.S. for its SARS-CoV-2 Antibody Test\t<\/a>\n<\/h4>\n\t\t

\n\t\t\tNew Zealand diagnostic biotech company Pictor Ltd. announced today that it has successfully completed validation trials at two separate sites in the United States, one of which was Florida-based Boca Biolistics, for its COVID-19 antibody test. \n\n\u201cWe were delighted with the performance observed in the Alpha studies which gave us confidence to rapidly proceed with trials in the USA,\u201d said Pictor Chief Technology Officer Dr. Richard Janeczko. \u201cWe feel the duplex nature of our test is a unique feature which provides much better data interpretation from serology testing for use the ongoing management of the global pandemic.\u201d \n\nThe company now aims to fast-track adoption of its low-cost, high-performance, high-throughput tests by obtaining FDA Emergency Use Authorization.\t\t<\/p>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/article>\n

\n\t
\n\t\t
\n\t\t
\n\t\t\n\t\t\t\"\"\t\t<\/a>\n\t\t\t<\/div>\n<\/div>\n\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\n\t\t\t\t29 September 2021\t<\/a>\n<\/div>\n
\n\t\tTechnology<\/a><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t
\n\t\t\t\t

\n\t\n\t\tPictor and SCIENION partner to commercialise high-throughput SARS-CoV-2 antibody testing system to support ongoing fight against pandemic\t<\/a>\n<\/h4>\n\t\t

\n\t\t\tPictor is excited to announce a strategic collaboration between Pictor and BICO Group’s Scienion for the international commercialisation a high throughput SARS-CoV-2 antibody testing system with Pictor\u2019s SARS-CoV-2 antibody assay and Scienion\u2019s CL2 reader\t\t<\/p>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/article>\n\t<\/div>\n\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Latest News September 25, 2022 Human Health Clinical Trials Pictor commences clinical trials for COVID\u201319 Antibodies in Aotearoa New Zealand. June 13, 2022 Animal HealthPRESS RELEASE Biotech Firm Tackling COVID-19 and M.bovis Announces Successful Development of Rapid, Accurate Johne\u2019s Disease Assay Auckland-based biotechnology company Pictor Limited has been developing an accurate, affordable multiplexed diagnostic test […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-2209","page","type-page","status-publish","hentry"],"yoast_head":"\nNews - Pictor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/odwstage.com\/dev.pictor.dx\/news\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News - Pictor\" \/>\n<meta property=\"og:description\" content=\"Latest News September 25, 2022 Human Health Clinical Trials Pictor commences clinical trials for COVID\u201319 Antibodies in Aotearoa New Zealand. June 13, 2022 Animal HealthPRESS RELEASE Biotech Firm Tackling COVID-19 and M.bovis Announces Successful Development of Rapid, Accurate Johne\u2019s Disease Assay Auckland-based biotechnology company Pictor Limited has been developing an accurate, affordable multiplexed diagnostic test […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/odwstage.com\/dev.pictor.dx\/news\/\" \/>\n<meta property=\"og:site_name\" content=\"Pictor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pictorltd\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-10T21:11:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dev.pictordx.com\/wp-content\/uploads\/2022\/11\/calf-5047986-1300x650.jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@PictorLtd\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/odwstage.com\/dev.pictor.dx\/news\/\",\"url\":\"https:\/\/odwstage.com\/dev.pictor.dx\/news\/\",\"name\":\"News - Pictor\",\"isPartOf\":{\"@id\":\"https:\/\/odwstage.com\/dev.pictor.dx\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/odwstage.com\/dev.pictor.dx\/news\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/odwstage.com\/dev.pictor.dx\/news\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.pictordx.com\/wp-content\/uploads\/2022\/11\/calf-5047986-1300x650.jpeg\",\"datePublished\":\"2021-11-23T08:21:09+00:00\",\"dateModified\":\"2022-11-10T21:11:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/odwstage.com\/dev.pictor.dx\/news\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/odwstage.com\/dev.pictor.dx\/news\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/odwstage.com\/dev.pictor.dx\/news\/#primaryimage\",\"url\":\"https:\/\/dev.pictordx.com\/wp-content\/uploads\/2022\/11\/calf-5047986-1300x650.jpeg\",\"contentUrl\":\"https:\/\/dev.pictordx.com\/wp-content\/uploads\/2022\/11\/calf-5047986-1300x650.jpeg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/odwstage.com\/dev.pictor.dx\/news\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/odwstage.com\/dev.pictor.dx\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/odwstage.com\/dev.pictor.dx\/#website\",\"url\":\"https:\/\/odwstage.com\/dev.pictor.dx\/\",\"name\":\"Pictor\",\"description\":\"Multiplexed technology for disease management\",\"publisher\":{\"@id\":\"https:\/\/odwstage.com\/dev.pictor.dx\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/odwstage.com\/dev.pictor.dx\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/odwstage.com\/dev.pictor.dx\/#organization\",\"name\":\"Pictor\",\"url\":\"https:\/\/odwstage.com\/dev.pictor.dx\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/odwstage.com\/dev.pictor.dx\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/odwstage.com\/dev.pictor.dx\/wp-content\/uploads\/2022\/11\/cropped-2020_Pictor-Logo_RGB.png\",\"contentUrl\":\"https:\/\/odwstage.com\/dev.pictor.dx\/wp-content\/uploads\/2022\/11\/cropped-2020_Pictor-Logo_RGB.png\",\"width\":1334,\"height\":336,\"caption\":\"Pictor\"},\"image\":{\"@id\":\"https:\/\/odwstage.com\/dev.pictor.dx\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/pictorltd\",\"https:\/\/x.com\/PictorLtd\",\"https:\/\/www.instagram.com\/pictorltd\/\",\"https:\/\/www.linkedin.com\/company\/pictorltd\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"News - Pictor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/odwstage.com\/dev.pictor.dx\/news\/","og_locale":"en_US","og_type":"article","og_title":"News - Pictor","og_description":"Latest News September 25, 2022 Human Health Clinical Trials Pictor commences clinical trials for COVID\u201319 Antibodies in Aotearoa New Zealand. June 13, 2022 Animal HealthPRESS RELEASE Biotech Firm Tackling COVID-19 and M.bovis Announces Successful Development of Rapid, Accurate Johne\u2019s Disease Assay Auckland-based biotechnology company Pictor Limited has been developing an accurate, affordable multiplexed diagnostic test […]","og_url":"https:\/\/odwstage.com\/dev.pictor.dx\/news\/","og_site_name":"Pictor","article_publisher":"https:\/\/www.facebook.com\/pictorltd","article_modified_time":"2022-11-10T21:11:10+00:00","og_image":[{"url":"https:\/\/dev.pictordx.com\/wp-content\/uploads\/2022\/11\/calf-5047986-1300x650.jpeg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@PictorLtd","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/odwstage.com\/dev.pictor.dx\/news\/","url":"https:\/\/odwstage.com\/dev.pictor.dx\/news\/","name":"News - Pictor","isPartOf":{"@id":"https:\/\/odwstage.com\/dev.pictor.dx\/#website"},"primaryImageOfPage":{"@id":"https:\/\/odwstage.com\/dev.pictor.dx\/news\/#primaryimage"},"image":{"@id":"https:\/\/odwstage.com\/dev.pictor.dx\/news\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.pictordx.com\/wp-content\/uploads\/2022\/11\/calf-5047986-1300x650.jpeg","datePublished":"2021-11-23T08:21:09+00:00","dateModified":"2022-11-10T21:11:10+00:00","breadcrumb":{"@id":"https:\/\/odwstage.com\/dev.pictor.dx\/news\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/odwstage.com\/dev.pictor.dx\/news\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/odwstage.com\/dev.pictor.dx\/news\/#primaryimage","url":"https:\/\/dev.pictordx.com\/wp-content\/uploads\/2022\/11\/calf-5047986-1300x650.jpeg","contentUrl":"https:\/\/dev.pictordx.com\/wp-content\/uploads\/2022\/11\/calf-5047986-1300x650.jpeg"},{"@type":"BreadcrumbList","@id":"https:\/\/odwstage.com\/dev.pictor.dx\/news\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/odwstage.com\/dev.pictor.dx\/"},{"@type":"ListItem","position":2,"name":"News"}]},{"@type":"WebSite","@id":"https:\/\/odwstage.com\/dev.pictor.dx\/#website","url":"https:\/\/odwstage.com\/dev.pictor.dx\/","name":"Pictor","description":"Multiplexed technology for disease management","publisher":{"@id":"https:\/\/odwstage.com\/dev.pictor.dx\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/odwstage.com\/dev.pictor.dx\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/odwstage.com\/dev.pictor.dx\/#organization","name":"Pictor","url":"https:\/\/odwstage.com\/dev.pictor.dx\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/odwstage.com\/dev.pictor.dx\/#\/schema\/logo\/image\/","url":"https:\/\/odwstage.com\/dev.pictor.dx\/wp-content\/uploads\/2022\/11\/cropped-2020_Pictor-Logo_RGB.png","contentUrl":"https:\/\/odwstage.com\/dev.pictor.dx\/wp-content\/uploads\/2022\/11\/cropped-2020_Pictor-Logo_RGB.png","width":1334,"height":336,"caption":"Pictor"},"image":{"@id":"https:\/\/odwstage.com\/dev.pictor.dx\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pictorltd","https:\/\/x.com\/PictorLtd","https:\/\/www.instagram.com\/pictorltd\/","https:\/\/www.linkedin.com\/company\/pictorltd\/"]}]}},"_links":{"self":[{"href":"https:\/\/odwstage.com\/dev.pictor.dx\/wp-json\/wp\/v2\/pages\/2209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/odwstage.com\/dev.pictor.dx\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/odwstage.com\/dev.pictor.dx\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/odwstage.com\/dev.pictor.dx\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/odwstage.com\/dev.pictor.dx\/wp-json\/wp\/v2\/comments?post=2209"}],"version-history":[{"count":49,"href":"https:\/\/odwstage.com\/dev.pictor.dx\/wp-json\/wp\/v2\/pages\/2209\/revisions"}],"predecessor-version":[{"id":12417,"href":"https:\/\/odwstage.com\/dev.pictor.dx\/wp-json\/wp\/v2\/pages\/2209\/revisions\/12417"}],"wp:attachment":[{"href":"https:\/\/odwstage.com\/dev.pictor.dx\/wp-json\/wp\/v2\/media?parent=2209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}